VRDNViridian Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Choppy, but holding above its 200-day average. Overbought (RSI 70). Price is +1% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How VRDN is trading
Viridian Therapeutics, Inc. is −2.8% over the past year while the S&P 500 is +16%: 19 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +0.94%
vs 200-day average · close to trend
- RSI (14)
- 70
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 34%
Below its 52-week high
Details›
- Last close2026-10-23
- $22.36
- 1 monthS&P 500 −0.94%
- +8.2%
- 1 yearS&P 500 +16%
- −2.8%
- 5 yearsS&P 500 +86%
- +43%
- vs 50-day average$21.57
- +3.7%
- 52-week high
- $33.78
- 52-week low
- $13.30
- Annualised volatility
- 65%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-22
- $20M
| Year | Return |
|---|---|
| 2026 (year to date) | −28% |
| 2025 | +62% |
| 2024 | −12% |
| 2023 | −25% |
| 2022 | +48% |
| 2021 | +20% |
| 2020 | +128% |
| 2019 | −84% |
| 2018 | −71% |
| 2017 | +108% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +34% |
| Feb | 10 | 1 of 10 | −10% |
| Mar | 10 | 3 of 10 | −9.1% |
| Apr | 10 | 6 of 10 | −1.5% |
| May | 10 | 4 of 10 | +2.3% |
| Jun | 10 | 6 of 10 | +1.8% |
| Jul | 11 | 7 of 11 | +5.7% |
| Aug | 11 | 3 of 11 | −4.0% |
| Sep | 11 | 5 of 11 | +0.56% |
| Oct | 11 | 4 of 11 | −0.13% |
| Nov | 10 | 6 of 10 | +17% |
| Dec | 10 | 4 of 10 | −4.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.